SEC Form 4 · accession 0001214659-26-010645
Twist Bioscience Corp · TWST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick John Finn
Officer — President and COO
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001581280
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 18, 2026 | M | 23,355 | $67.85 | A | 293,033 | D | |
| Common StockF2 | Aug 18, 2026 | S | 33,354 | $115.899 | D | 259,679 | D | |
| Common StockF3 | Aug 18, 2026 | S | 10,420 | $116.8202 | D | 249,259 | D | |
| Common StockF4 | Aug 18, 2026 | S | 8,868 | $117.697 | D | 240,391 | D | |
| Common StockF5 | Aug 18, 2026 | S | 4,500 | $119.04 | D | 235,891 | D | |
| Common StockF6 | Aug 18, 2026 | S | 12,917 | $119.858 | D | 222,974 | D | |
| Common StockF7 | Aug 18, 2026 | S | 6,296 | $121.007 | D | 216,678 | D | |
| Common StockF8 | Aug 18, 2026 | S | 2,000 | $122.581 | D | 214,678 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F9 | $67.85 | Aug 18, 2026 | M | 23,355 | D | — | Aug 31, 2030 | Common Stock | 23,355 | 0 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 18, 2026.
- F2Represents the weighted average sales price per share. The shares sold at prices ranging from $115.35 to $116.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3Represents the weighted average sales price per share. The shares sold at prices ranging from $116.37 to $117.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4Represents the weighted average sales price per share. The shares sold at prices ranging from $117.37to $118.19 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5Represents the weighted average sales price per share. The shares sold at prices ranging from $118.505 to $119.45 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F6Represents the weighted average sales price per share. The shares sold at prices ranging from $119.515 to $120.2 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F7Represents the weighted average sales price per share. The shares sold at prices ranging from $120.585 to $121.53 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F8Represents the weighted average sales price per share. The shares sold at prices ranging from $122.00 to $122.815 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F9The option was 100% exercisable on December 19, 2022.